BMI The London Independent Hospital has become the UK’s first hospital to launch Spartan RX, a bedside DNA test, to identify patients resistant to clopidogrel, the blood-thinning drug.
The new genetic test identifies the CYP2C19*2 gene, present in 30% of the world’s population, which can impair the delivery of clopidogrel.
BMI The London Independent Hospital consultant cardiologist Dr Charles Knight said the new Spartan RX test has the potential to improve the outcomes of patients having coronary stents.
"Before a patient undergoes balloon treatment and stenting their medical team can identify if they have an increased risk of further cardiac complications," Knight added.
"Spartan RX quickly and accurately delivers a result that can help determine what medication should be prescribed in order to achieve the best results for a patient."
Clopidogrel, which is administered to patients before and after surgery to thin their blood and prevent clots developing within the stent, cannot be fully metabolised by the body into its working state in patients with the CYP2C19*2 gene defect.
Spartan RX allows the consultant cardiologist team to identify, at the pre-assessment stage, if the patient is a carrier of the gene and adjust the treatment accordingly.
Nurses can operate the system, which delivers results in one hour from a cheek swab, hospital officials said.
BMI The London Independent Hospital executive director Kirsty Baker said, "Genetic testing will allow our cardiologists to deliver to our patients tailored treatment plans and we predict that, as this test becomes widespread across the UK, it has the potential to help improve outcomes for our patients."
Image: Dr Knight (centre) with BMI The London Independent Hospital’s cardiac team. Photo: BMI Healthcare.